GeoVax Labs, Inc. (GOVX): Price and Financial Metrics

GeoVax Labs, Inc. (GOVX): $0.65

0.03 (+4.85%)

POWR Rating

Component Grades













Add GOVX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where GOVX ranks best; there it ranks ahead of 61.6% of US stocks.
  • GOVX's strongest trending metric is Quality; it's been moving up over the last 178 days.
  • GOVX's current lowest rank is in the Stability metric (where it is better than 1.04% of US stocks).

GOVX Stock Summary

  • For GOVX, its debt to operating expenses ratio is greater than that reported by only 0.44% of US equities we're observing.
  • With a price/sales ratio of 66.35, GEOVAX LABS INC has a higher such ratio than 96.9% of stocks in our set.
  • GEOVAX LABS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -169.54%, greater than the shareholder yield of only 3.76% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GEOVAX LABS INC are IVA, ACIU, IMMP, GRNA, and ARAV.
  • GOVX's SEC filings can be seen here. And to visit GEOVAX LABS INC's official web site, go to

GOVX Valuation Summary

  • In comparison to the median Healthcare stock, GOVX's EV/EBIT ratio is 87.79% lower, now standing at 0.8.
  • GOVX's EV/EBIT ratio has moved up 213.2 over the prior 199 months.

Below are key valuation metrics over time for GOVX.

Stock Date P/S P/B P/E EV/EBIT
GOVX 2023-03-17 66.7 0.5 -0.7 0.8
GOVX 2023-03-16 72.4 0.6 -0.8 0.8
GOVX 2023-03-15 69.9 0.5 -0.8 0.8
GOVX 2023-03-14 69.5 0.5 -0.8 0.8
GOVX 2023-03-13 73.2 0.6 -0.8 0.7
GOVX 2023-03-10 72.8 0.6 -0.8 0.8

GOVX Growth Metrics

    Its 2 year revenue growth rate is now at -76.66%.
  • The year over year cash and equivalents growth rate now stands at -21.99%.
  • Its 3 year revenue growth rate is now at -67.76%.
Over the past 30 months, GOVX's revenue has gone down $1,281,153.

The table below shows GOVX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.246488 -18.64912 -22.38032
2022-06-30 0.276902 -16.48367 -20.36272
2022-03-31 0.35661 -13.90863 -19.43505
2021-12-31 0.385501 -11.19642 -18.57032
2021-09-30 0.47216 -6.055222 -6.163836
2021-09-30 0.47216 -6.055222 -6.163836

GOVX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GOVX has a Quality Grade of D, ranking ahead of 16.15% of graded US stocks.
  • GOVX's asset turnover comes in at 0.054 -- ranking 535th of 563 Business Services stocks.
  • CELP, PGEN, and V are the stocks whose asset turnover ratios are most correlated with GOVX.

The table below shows GOVX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.054 1 24.528
2021-03-31 0.110 1 5.871
2020-12-31 0.305 1 2.439
2020-09-30 0.525 1 1.312
2020-06-30 2.288 1 1.130
2020-06-30 2.288 1 1.130

GOVX Price Target

For more insight on analysts targets of GOVX, see our GOVX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.00 Average Broker Recommendation 1.5 (Moderate Buy)

GOVX Stock Price Chart Interactive Chart >

Price chart for GOVX

GOVX Price/Volume Stats

Current price $0.65 52-week high $4.30
Prev. close $0.62 52-week low $0.53
Day low $0.63 Volume 115,271
Day high $0.69 Avg. volume 2,086,257
50-day MA $0.77 Dividend yield N/A
200-day MA $1.09 Market Cap 17.15M

GeoVax Labs, Inc. (GOVX) Company Bio

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

GOVX Latest News Stream

Event/Time News Detail
Loading, please wait...

GOVX Latest Social Stream

Loading social stream, please wait...

View Full GOVX Social Stream

Latest GOVX News From Around the Web

Below are the latest news stories about GEOVAX LABS INC that investors may wish to consider to help them evaluate GOVX as an investment opportunity.

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated forBest Academic/Research Team Award ATLANTA, GA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against solid tumor cancers and infectious diseases, today congratulates its colleague and collaborator, Don Diamond, Ph.D. for recognition as a finalist for the Best Academic/Research Team Award, part of the Vaccine Industry Excellence

Yahoo | March 15, 2023

GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday, March 23, 2023 after the market closes. Following the release, management will host a live conference call and webcast to provide a gen

Yahoo | March 9, 2023

GeoVax to Participate at the 35th Annual Roth Conference

Company Progress to be Discussed During Analyst-Led Fireside Chat ATLANTA, GA, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will discuss the company’s progress with Senior Research Analyst Kumaragura Raja, Ph.D. from ROTH MKM. The discussion will take place during a fireside chat at the 35th Ann

Yahoo | March 6, 2023

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

Data Presented Indicated Very High Levels of Immunogenicity of the Combinational Therapy ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax’s HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviru

Yahoo | February 27, 2023

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

Mobile Community Clinical Research Facility to be Deployed in California ATLANTA, GA, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial global organization, today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax’s ongoing Phase 2 cli

Yahoo | February 15, 2023

Read More 'GOVX' Stories Here

GOVX Price Returns

1-mo -22.62%
3-mo 12.85%
6-mo -40.37%
1-year -56.38%
3-year -88.56%
5-year -100.00%
YTD 3.14%
2022 -82.59%
2021 7.10%
2020 -71.83%
2019 -100.00%
2018 -52.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8344 seconds.